Evaluating Blue Zones Demography in Response to Recent Critiques
January 6, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Taxol
(United States) [Available]Synonyms :
Paclitaxel
Class :
Taxanes
Brand Name :
Taxol
(United States) [Available]Synonyms :
Paclitaxel
Class :
Taxanes
Dosage Forms & Strengths:
Injectable solution:
6mg per ml
untreated patients:
175
mg/m^2
Intravenous (IV)
Over 3 hr
given over 3hrs followed by cisplatin 75 mg per m2 IV for every three weeks or else 135 mg per m2 IV given 24hrs followed by cisplatin 75 mg per m2 IV every three weeks.
patients previously treated: 135 mg per m2 IV over 3hrs for every three weeks or else 175 mg per m2 IV over 3hrs for every three weeks
adjuvant treatment: 175 mg/m2 IV over 3hrs 3 weeks for four courses administered sequentially to doxorubicin containing chemotherapy :
175
mg
Intravenous (IV)
over 3 hr
3
weeks
135
mg/m^2
iv
over 24hrs followed by cisplatin IV for every three weeks
135
mg/m^2
iv
over 3 hr
3
weeks
when both drugs are combined, the metabolism of paclitaxel increases
when both drugs are combined, the metabolism of paclitaxel increases
when both drugs are combined, the metabolism of paclitaxel increases
when both drugs are combined, the metabolism of baricitinib increases
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, the metabolism of paclitaxel decreases when compared with boceprevir
when both drugs are combined, the metabolism of paclitaxel increases when compared with certolizumab pegol
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of neutropenia
when both drugs are combined, the metabolism of paclitaxel decreases when compared with delavirdine
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
when both drugs are combined, the metabolism of paclitaxel increases when compared with etanercept
when both drugs are combined, there may be an increased immunosuppressive effect of fingolimod by paclitaxel
when both drugs are combined, the metabolism of paclitaxel decreases when compared with fosamprenavir
when both drugs are combined, the metabolism of paclitaxel increases when compared with golimumab
when both drugs are combined, the metabolism of paclitaxel decreases when compared with indinavir
when both drugs are combined, the metabolism of paclitaxel increases when compared with infliximab
influenza virus vaccine h n live
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
influenza virus vaccine live trivalent
when both drugs are combined, there may be an increased risk or severity of disease from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased therapeutic efficacy of the measles virus vaccine
when both drugs are combined, there may be a decreased therapeutic efficacy of the mumps virus vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, the metabolism of paclitaxel decreases when compared with nelfinavir
when both drugs are combined, the metabolism of paclitaxel decreases when compared with ozanimod
when both drugs are combined, the metabolism of paclitaxel decreases when compared with ponesimod
when both drugs are combined, there may be an increased level of serum concentration of paclitaxel
when both drugs are combined, there may be a decreased therapeutic efficacy of the rotavirus vaccine
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, the metabolism of paclitaxel decreases when compared with saquinavir
when both drugs are combined, the metabolism of siponimod increases
when both drugs are combined, there may be a decreased therapeutic efficacy of the smallpox vaccine
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of peripheral neuropathy
when both drugs are combined, there may be an increased immunosuppressive activity of tofacitinib
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of disease from the vaccine
may increase serum concentrations of doxorubicin
sorafenib increases the toxic/adverse effects of paclitaxel
when both drugs are combined, there may be an increased the serum concentration of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine
when both drugs are combined, there may be an increased metabolism of ado-trastuzumab emtansine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased the serum concentration of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be an increased the serum concentration of paclitaxel
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased the serum concentration of paclitaxel
when both drugs are combined, there may be an increased the serum concentration of bexarotene
when both drugs are combined, there may be an increased metabolism of bicalutamide
when both drugs are combined, there may be a high metabolism of bortezomib
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of brentuximab
when both drugs are combined, there may be an increased metabolism of brigatinib
butabarbital may increase the hypotensive activities of paclitaxel
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of cabazitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a decreased level of serum concentration of capmatinib
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased level of serum concentration of paclitaxel
when both drugs are combined, there may be an increased metabolism of ceritinib
when both drugs are combined, there may be a high metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of dabrafenib
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of erdafitinib
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be a high metabolism of paclitaxel
when both drugs are combined, there may be a decreased rate of excretion of paclitaxel
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of hypotension and orthostatic hypotension
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased metabolism of neratinib
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a reduced level of serum concentration of nitrofurantoin by a decreased rate of excretion
when both drugs are combined, there may be an increased immunosuppressive activity of paclitaxel
when both drugs are combined, there may be an increased risk or severity of myopathy, rhabdomyolysis, and myoglobinuria
when both drugs are combined, there may be an increased immunosuppressive activity of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced level of serum concentration of tinidazole by a reduced rate of excretion
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of tolvaptan
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased metabolism of trabectedin
when both drugs are combined, there may be a decreased level of serum concentration of paclitaxel
when both drugs are combined, there may be an increased metabolism of ulipristal
when both drugs are combined, there may be a high metabolism of vemurafenib
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be an increased neurotoxic activity of vinorelbine
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a reduced metabolism of paclitaxel
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
when both drugs are combined, there may be an increased effect of paclitaxel by p-glycoprotein (mdr1) efflux transporter
the effect of paclitaxel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
fedratinib increases the effect of paclitaxel by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
may decrease the level of each other
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
when both drugs are combined, there may be an increased metabolism of paclitaxel
when both drugs are combined, there may be an increased level of serum of moxifloxacin
when both drugs are combined, there may be an increased risk or severity of myopathy, rhabdomyolysis, and myoglobinuria
when both drugs are combined, there may be an increased level of serum of ofloxacin
Actions and spectrum:
The regular process of microtubule growth is disrupted by paclitaxel. Paclitaxel specifically binds to tubulin’s β subunit. The “building block” of microtubules is tubulin, which is locked in place by paclitaxel binding. The resulting microtubule-paclitaxel complex cannot disassemble. As a result, there is a negative impact on cell function because microtubules’ role as the cell’s transportation network—which is dependent on their dynamic instability—is negatively impacted. During mitosis, for instance, chromosomes depend on this characteristic of microtubules. According to additional research, paclitaxel causes cancer cells to go through processes like apoptosis or programmed cell death by inhibiting the activity of the apoptosis-inducing protein Bcl-2 (B-cell leukemia 2).
Adverse drug reactions:
Frequency defined
>10%
Alopecia
Anemia
Arthralgia
Diarrhea
Hypersensitivity
Hypotension
Leukopenia
Mucositis
Nausea
Neutropenia
Opportunistic infections
Peripheral neuropathy
Renal impairment
Thrombocytopenia
vomiting
1-10%
Bradycardia
<1%
Cardiac conduction abnormalities
Grand mal seizures
Frequency Not Defined
Congestive heart failure
Dehydration
Extravasation
Left ventricular dysfunction
Pancytopenia
Pyrexia
Stevens Johnson Syndrome
toxic epidermal necrolysis
Black Box Warning
A very important caution comes with paclitaxel, a medication that must never be used during pregnancy.
Contraindication/Caution:
Contraindication:
Liver disease
Pregnancy
Lactation
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pharmacology:
Paclitaxel is a medicine that stops cancer cells from dividing. It treats breast, lung, ovarian, and other cancers. Paclitaxel disrupts the normal division of cells, preventing cancer growth and spread. Cancer cells divide rapidly, so this medicine targets them. Doctors use paclitaxel in chemo regimens for these cancer types.
Pharmacodynamics:
Paclitaxel treats several kinds of cancer. It’s a drug used for therapy. This chemical interferes with microtubules. It stabilizes these structures inside cells. That disrupts normal function and cell division. Paclitaxel prevents microtubules from breaking down. It also makes extra microtubules form incorrectly. The resulting abnormal microtubule arrays stop cells working normally. This happens during interphase and mitosis. The cycles cells go through to grow and divide. Other malignancies use paclitaxel as a treatment too. These include advanced ovarian and breast cancers specifically.
Pharmacokinetics:
Distribution
A lot of paclitaxel, around 89-98%, binds to proteins in the body. Its volume spans 227 to 688 L/sq.mt.
Metabolism
The liver enzymes CYP3A4 and CYP2C8 break it down. The main byproduct is 6-alpha-hydroxy paclitaxel.
Elimination and excretion
As for getting rid of it, around 20% leaves through feces. Roughly 4% exits via urine. Its half-life is about 27 hours. This drug takes a while to fully clear from the system.
Administration:
People receive paclitaxel through an IV. Doctors decide the dosage based on the patient’s health, treatment results, and body size.
Patient Information Leaflet:
Paclitaxel is a medicine used to treat cancer. Doctors give it through injections. While helpful for various cancers, it may cause shortness of breath or dizziness and muscle aches. Before starting treatment, let your doctor know if you have any allergies. Men shouldn’t father children while taking this drug. Pregnant women must inform their doctors. Don’t breastfeed during treatment. An overdose is dangerous – call poison control right away. If you miss a dose, reschedule with your doctor immediately. Keep this medicine away from kids and pets, stored safely.
Pronunciation: PAK-li-TAK-sel
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
